• Home
  • Respiratory diseases Publications

Respiratory diseases Publications

Respiratory diseases Publications

  • Which long-acting bronchodilator is most cost-effective for the treatment of COPD?.Abstract

    Background: The aim of this study was to estimate the cost-effectiveness of tiotropium versus salmeterol to inform decision making within the Dutch healthcare setting. Methods: A previously published, validated COPD progression model was updated wih new exacerbation data and adapted to the Dutch setting by including Dutch estimates of healthcare use for COPD maintenance treatment and Dutch unit costs

    Hoogendoorn M, Kappelhoff BS, Overbeek JA, Wouters EF, Rutten-van Molken MP. Neth J Med. 2012 Oct; 70 (8): 357-64.
  • Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis.Abstract

    BACKGROUND: Long-acting muscarinic antagonists (LAMA), long-acting beta2-agonists (LABA) and fixed dose combinations (FDC) of inhaled corticosteroids (ICS) and LABA are used as inhaled maintenance therapies for COPD. OBJECTIVE: To estimate persistece rates from dispensing patterns of long-acting inhaled drugs for COPD

    Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Respir Med. 2011 Feb; 105 (2): 259-65.
  • Evaluation of smoking cessation drug use and outcomes in the Netherlands.Abstract

    OBJECTIVE: Several pharmacological therapies are available to help smokers quit. The aim was to investigate the utilisation and effectiveness of smoking cessation drugs in daily practice in the Netherlands. METHODS: Subjects aged >/=18 years with apharmacy prescription of varenicline, bupropion, nicotine replacement therapy (NRT) or nortriptyline between March 2007 and September 2008 were identified from the PHARMO data warehouse, which includes drug dispensing, hospitalisation and other data fromapproximately 2

    Penning-van Beest FJ, Overbeek JA, Smulder s M, van Spiegel PI, Meerding WJ, Herings RM. J Med Econ. 2011 14 (1): 124-9.
  • Measuring exacerbations in obstructive lung disease.Abstract

    PURPOSE: Using hospitalization always has been seen as a solid measurement for exacerbation in pharmacoepidemiology, but might lead to an underestimation of disease exacerbation because of a trend towards outpatient care. The aim of this study waso quantify the incidence of different exacerbation markers in obstructive lung disease and to identify predictors for these exacerbation markers

    Velthove KJ, Souverein PC, van Solinge WW, Leufkens HG, Lammers JW. Pharmacoepidemiol Drug Saf. 2010 Apr; 19 (4): 367-74.
  • Medication changes prior to hospitalization for obstructive lung disease: a case-crossover study.Abstract

    BACKGROUND: Hospitalizations have always been seen as a solid outcome parameter in pharmacoepidemiology. However, the period leading to hospitalization and prehospital management of the patient are equally important. OBJECTIVE: To evaluate medicatin changes in the period prior to hospitalization for obstructive lung disease and to quantify the association between medication use and the risk of hospitalization

    Velthove KJ, Leufkens HG, Schweizer RC, van Solinge WW, Souverein PC. Ann Pharmacother. 2010 Feb; 44 (2): 267-73.
  • Effects of corticosteroid use on readmission in obstructive lung disease.Abstract

    OBJECTIVE: Obstructive lung disease is a leading cause of morbidity and mortality worldwide. Some patients are readmitted, but currently predicting parameters for identifying these patients are lacking. The aim of this study was to quantify the incdence of readmission in chronic obstructive lung disease and to identify determinants for hospital readmission

    Velthove KJ, Souverein PC, van Solinge WW, Leufkens HG, Lammers JW. Respir Med. 2010 Feb; 104 (2): 211-8.
  • Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study.Abstract

    OBJECTIVES: The risk of a subsequent exacerbation after treatment of an exacerbation with oral corticosteroids without (OS) or with (OSA) antibiotics was evaluated in a historical population based cohort study comprising patients using maintenanceedication for obstructive lung disease. METHODS: The Pharmo database includes drug dispensing records of more than 2 million subjects in The Netherlands

    Roede BM, Bresser P, Binde ls PJ, Kok A, Prins M, terRiet G, Geskus RB, Herings RM, Prins JM. Thorax. 2008 Nov; 63 (11): 968-73.
  • Antipsychotic drug use and risk of pneumonia in elderly people.Abstract

    OBJECTIVES: To investigate the association between antipsychotic drug use and risk of pneumonia in elderly people. DESIGN: A nested case-control analysis. SETTING: Data were used from the PHARMO database, which collates information from community parmacies and hospital discharge records. PARTICIPANTS: A cohort of 22,944 elderly people with at least one antipsychotic prescription; 543 cases of hospital admission for pneumonia were identified

    Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. J Am Geriatr Soc. 2008 Apr; 56 (4): 661-6.
  • Extent of uncontrolled disease and associated medical costs in severe asthma–a PHARMO study.Abstract

    OBJECTIVE: Asthma is a major public health problem with considerable economic impact. The highest costs being observed in patients with severe asthma. Furthermore, despite the use of recommended therapies, asthma control can still be poor. Therefor, the objective of this study was to assess the extent of uncontrolled disease and associated medical costs in severe asthma

    Breekveldt-Postma NS, Erkens JA, Aalbers R, van de Ven MJ, Lammers JW, Herings RM. Curr Med Res Opin. 2008 Apr; 24 (4): 975-983.
  • Treatment with inhaled corticosteroids in asthma is too often discontinued.Abstract

    PURPOSE: To study persistence with inhaled corticosteroids (ICS) and its determinants in asthma-patients. METHODS: From the PHARMO database, asthma-patients (age < 35 years) with a first dispensing for ICS in 1999-2002 and >/= 2 dispensings in theirst year were included. Persistence during the first year was defined as the number of days from start to time of first failure to continue renewal of the initial ICS

    Breekveldt-Postma NS, Koerselman J, Erkens JA, van der Molen T, Lammers JW, Herings RM. Pharmacoepidemiol Drug Saf. 2008 Apr; 17 (4): 411-422.